Metformin

New England Journal of Medicine

Volumn 334, Issue 9, 1996, Pages 574-579

  Bailey, Clifford J ^a   Turner, Robert C ^b  

^a ASTON UNIVERSITY   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; SULFONYLUREA DERIVATIVE; BIGUANIDE; SULFONYLUREA;

CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; HUMAN; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; CALORIC INTAKE; CARBOHYDRATE INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG MECHANISM; FATTY ACID OXIDATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT PLANNING;

ACIDOSIS, LACTIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS;

EID: 0030605388     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/nejm199602293340906     Document Type: Review

References (66)

1. Bailey CJ Biguanides and NIDDM Diabetes Care 1992; 15 755-72
2. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987,36:523-34.
3. Gall MA, Rossing P, Skott P, et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991,34 655-61.
4. Nathan DM Long-term complications of diabetes mellitus. N Engl J Med 1993,328:1676-85
5. Garcia MJ, McNamara PM, Gordon T, Kannell WB. Morbidity and mortality in diabetics in the Framingham population, sixteen year follow-up study Diabetes 1974;23:105-11.
6. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123-31 [Erratum, Diabetologia 1987;30: 364]
7. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
8. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulm-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
9. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II Mortality results Diabetes 1970, 19:Suppl:789-830.
10. American Diabetes Association Standards of medical care for patients with diabetes mellitus Diabetes Care 1994;17:616-23
11. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994, 17.1100-9
12. U.K. Prospective Diabetes Study Group, U.K. Prospective Diabetes Study 16: progressive nature of type 2 diabetes. Diabetes 1995,44:1249-58
13. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37: 1595-607.
14. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991,14:173-94.
15. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care 1990,13. 631-54
16. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM a balanced overview. Diabetes Care 1992,15.318-68.
17. 13C nuclear magnetic resonance spectroscopy N Engl J Med 1990;322.223-8.
18. Consoli A, Nurjhan N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989; 38:550-7.
19. Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 1989;38:767-72.
20. Porte D Jr. B-cells in type II diabetes mellitus. Diabetes 1991;40:166-80.
21. Rudenski AS, Hadden DR, Atkinson AB, et al. Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment Diabetic Med 1985;5:36-41.
22. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8
23. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients Metabolism 1990;39:905-12.
24. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321 1231-45.
25. Groop LC. Sulfonylureas in NIDDM Diabetes Care 1992;15:737-54.
26. Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989;12.553-64.
27. Sterne J Pharmacology and mode of action of hypoglycaemic guanidine derivatives. In: Campbell GD, ed Oral hypoglycaemic agents. London: Academic, 1969.193-245.
28. Beckmann R. Biguanide (Experimenteller Teil). In: Maske H, ed. Oral wirksame Antidiabetika Vol 29 of Handbuch der experimentellen Pharmakologie Berlin, Germany: Springer-Verlag, 1971:439-596
29. Nattrass M, Alberti KGMM. Biguanides. Diabetologia 1978;14:71-4.
30. Hermann LS, Melander A Biguanides: basic aspects and clinical uses In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International textbook of diabetes mellitus. Vol. 1. Chichester, England. John Wiley, 1992 773-95
31. Bailey CJ Metformin - an update. Gen Pharmacol 1993;24:1299-309
32. Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action is non-insulin-dependent diabetes. Diabetes 1987;36.632-40
33. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294-301.
34. Reaven GM, Johnston P, Hollenbeck CB, et al. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 1992;74.1020-6.
35. Boyd K, Rogers C, Boreham C, Andrews WJ, Hadden DR. Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes, heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. Diabetes Res 1992,19.69-76.
36. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
37. Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin, synergism with insulin. Biochem Pharmacol 1988;37:4353-8.
38. Bailey CJ, Puah JA Effect of metformin on glucose metabolism in mouse soleus muscle. Diabete Metab 1986;12:212-8.
39. Rossetti L, DeFronzo RA, Gherzi R, et al. Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations Metabolism 1990;39.425-35.
40. Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 1994;37:826-32
41. Cigolini M, Bosello O, Zancanaro C, Orlandi PG, Fezzi O, Smith U. Influence of metformin on metabolic effect of insulin in human adipose tissue in vitro. Diabete Metab 1984;10.311-5.
42. Matthaei S, Hamann A, Klein HH, et al. Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytcs. Diabetes 1991;40:850-7.
43. Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells Endocrinology 1992;131:1165-73
44. Matthaei S, Reibold JP, Hamann A. et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology 1993,133 304-11.
45. Melin B, Cherqui G, Blivet MJ, et al. Dual effect of metformin in cultured rat hepatocytes: potentiation of insulin action and prevention of insulin-induced resistance. Metabolism 1990;39:1089-95.
46. Kozka IJ, Holman GD. Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes 1993;42:1159-65.
47. Wu MS, Johnston P, Sheu WHH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990;13:1-8.
48. Groop L, Widen E, Franssila-Kallunki A, et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989,32:599-605.
49. Riccio A, Del Prato S, de Kreutzenberg SV, Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes: effect of metformin. Diabete Metab 1991;17:180-4.
50. Perriello G, Misericordia P, Volpi E, et al Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production Diabetes 1994;43:920-8.
51. Bailey CJ, Nattrass M Treatment - metformin. Baillieres Clin Endocrinol Metab 1988,2:455-76
52. Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 1992;105:1009-13.
53. Penicaud L, Hitier Y, Ferre P, Girard T. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J 1989;262:881-5.
54. Nagi DK, Yudkin JS Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 1993;16:621-9.
55. Grant PJ, Stickland MH, Booth NA, Prentice CRM. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabetic Med 1991;8.361-5.
56. Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. BMJ 1977;2: 1576-8.
57. Bailey CJ. Hypoglycaemic, antihyperglycaemic and antidiabetic drugs. Diabetic Med 1992,9:482-3.
58. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23 545-51.
59. Dandona P, Fonseca V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. Diabetes Care 1983;6:472-4.
60. Hermann LS Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care 1990;13:Suppl 3:37-41.
61. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9
62. Campbell IW. Metformin and glibenclamide: comparative risks. BMJ 1984; 289:289.
63. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994,11:223-41.
64. Lalau JD, Andrejak M, Moriniere P, et al. Hemodialysis in the treatment of lactic acidosis in diabetic treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 1989;27:285-8.
65. Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis: case report and review of the literature. Arch Intern Med 1992;152:2333-6.
66. Oates NS, Shah RR, Idle JR, Smith RL. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther 1983;34: 827-34